The kinin–kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers

References

• Abdullah-Soheimi SS, Lim BK, Hashim OH, Shuib AS. (2010). Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin. Proteome Sci 8:58
   PubMed Web of Science ®Google Scholar
• Acuna-Castillo C, Aravena M, Leiva-Salcedo E, et al. (2005). T-kininogen, a cystatin-like molecule, inhibits ERK-dependent lymphocyte proliferation. Mech Ageing Dev 126:1284–91
   PubMed Web of Science ®Google Scholar
• Anderson KP, Croyle ML, Lingrel JB. (1989). Primary structure of a gene encoding rat T-kininogen. Gene 81:119–28
   PubMed Web of Science ®Google Scholar
• Asakura S, Yang W, Sottile J, et al. (1998). Opposing effects of low and high molecular weight kininogens on cell adhesion. J Biochem 124:473–84
   PubMed Web of Science ®Google Scholar
• Avgeris M, Mavridis K, Scorilas A. (2010). Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem 391:505–11
   PubMed Web of Science ®Google Scholar
• Avgeris M, Papachristopoulou G, Polychronis A, Scorilas A. (2011). Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. Clin Proteomics 8:5
   PubMedGoogle Scholar
• Barbasz A, Guevara-Lora I, Rapala-Kozik M, Kozik A. (2008). Kininogen binding to the surfaces of macrophages. Int Immunopharmacol 8:211–16
   PubMed Web of Science ®Google Scholar
• Barbasz A, Kozik A. (2009). The assembly and activation of kinin-forming systems on the surface of human U-937 macrophage-like cells. Biol Chem 390:269–75
   PubMed Web of Science ®Google Scholar
• Beck C, Piontek G, Haug A, et al. (2012). The kallikrein–kinin-system in head and neck squamous cell carcinoma (HNSCC) and its role in tumour survival, invasion, migration and response to radiotherapy. Oral Oncol 48:1208–19
   PubMed Web of Science ®Google Scholar
• Bior AD, Pixley RA, Colman RW. (2007). Domain 5 of kininogen inhibits proliferation of human colon cancer cell line (HCT-116) by interfering with G1/S in the cell cycle. J Thrombosis Haemostasis: JTH 5:403–11
   Web of Science ®Google Scholar
• Boels K, Schaller HC. (2003). Identification and characterisation of GPR100 as a novel human G-protein-coupled bradykinin receptor. Br J Pharmacol 140:932–8
   PubMed Web of Science ®Google Scholar
• Borgono CA, Michael IP, Diamandis EP. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2:257–80
   PubMed Web of Science ®Google Scholar
• Bossi F, Peerschke EI, Ghebrehiwet B, Tedesco F. (2011). Cross-talk between the complement and the kinin system in vascular permeability. Immunol Lett 140:7–13
   PubMed Web of Science ®Google Scholar
• Bourdet B, Pecher C, Minville V, et al. (2010). Distribution and expression of B2-kinin receptor on human leukocyte subsets in young adults and elderly using flow cytometry. Neuropeptides 44:155–61
   PubMed Web of Science ®Google Scholar
• Browder T, Folkman J, Pirie-Shepherd S. (2000). The hemostatic system as a regulator of angiogenesis. J Biol Chem 275:1521–4
   PubMed Web of Science ®Google Scholar
• Brunnee T, Reddigari SR, Shibayama Y, et al. (1997). Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy: J Br Soc Allergy Clin Immunol 27:653–63
   PubMed Web of Science ®Google Scholar
• Butt SK, Dawson LG, Hall JM. (1995). Bradykinin B1 receptors in the rabbit urinary bladder: induction of responses, smooth muscle contraction, and phosphatidylinositol hydrolysis. Br J Pharmacol 114:612–17
   PubMed Web of Science ®Google Scholar
• Campbell DJ. (2003). Vasopeptidase inhibition: a double-edged sword? Hypertension 41:383–9
   PubMed Web of Science ®Google Scholar
• Carroll VA, Binder BR. (1999). The role of the plasminogen activation system in cancer. Sem Thrombosis Hemostasis 25:183–97
   PubMed Web of Science ®Google Scholar
• Chan DW, Bruzek DJ, Oesterling JE, et al. (1987). Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. Clin Chem 33:1916–20
   PubMed Web of Science ®Google Scholar
• Chao J, Simson JA, Chung P, et al. (1993). Regulation of kininogen gene expression and localization in the lung after monocrotaline-induced pulmonary hypertension in rats. Proc Soc Exp Biol Med 203:243–50
   PubMed Web of Science ®Google Scholar
• Chee J, Naran A, Misso NL, et al. (2008). Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer. Biol Chem 389:1225–33
   PubMed Web of Science ®Google Scholar
• Chen Z, Deddish PA, Minshall RD, et al. (2006). Human ACE and bradykinin B2 receptors form a complex at the plasma membrane. FASEB J: Off Publ Federation Am Soc Exp Biol 20:2261–70
   PubMed Web of Science ®Google Scholar
• Cheung PP, Kunapuli SP, Scott CF, et al. (1993). Genetic basis of total kininogen deficiency in Williams' trait. J Biol Chem 268:23361–5
   PubMed Web of Science ®Google Scholar
• Choi SH, Smith SA, Morrissey JH. (2011). Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 118:6963–70
   PubMed Web of Science ®Google Scholar
• Chung DW, Fujikawa K, McMullen BA, Davie EW. (1986). Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 25:2410–17
   PubMed Web of Science ®Google Scholar
• Colman RW. (1996). Inhibitory and antiadhesive properties of human kininogens. Immunopharmacology 32:9–18
   PubMedGoogle Scholar
• Colman RW. (2006). Regulation of angiogenesis by the kallikrein-kinin system. Curr Pharmaceutical Des 12:2599–607
   PubMed Web of Science ®Google Scholar
• Colman RW, Jameson BA, Lin Y, et al. (2000). Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 95:543–50
   PubMed Web of Science ®Google Scholar
• Colman RW, Schmaier AH. (1997). Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90:3819–43
   PubMed Web of Science ®Google Scholar
• Colman RW, White JV, Scovell S, et al. (1999). Kininogens are antithrombotic proteins in vivo. Arteriosc Thrombosis Vas Biol 19:2245–50
   PubMed Web of Science ®Google Scholar
• Colman RW, Wu Y, Liu Y. (2010). Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signalling. Thrombosis Haemostasis 104:875–85
   PubMed Web of Science ®Google Scholar
• Costerousse O, Jaspard E, Allegrini J, et al. (1992). Angiotensin converting enzyme (kininase II). Molecular and physiological aspects. C R Soc Biol Filiales 186:586–98
   PubMedGoogle Scholar
• Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. (1993). Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 290:33–40
   PubMed Web of Science ®Google Scholar
• Czokało M, Pałka M, Kralisz P, Filipkowski T. (1996). Kallikrein-kinin system in patients with neoplastic diseases. Rocz Akad Med Bialymst 41:417–28
   PubMedGoogle Scholar
• Danilov S, Jaspard E, Churakova T, et al. (1994). Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies. Selective inhibition of the amino-terminal active site. J Biol Chem 269:26806–14
   PubMed Web of Science ®Google Scholar
• Daub H, Wallasch C, Lankenau A, et al. (1997). Signal characteristics of G protein-transactivated EGF receptor. EMBO J 16:7032–44
   PubMed Web of Science ®Google Scholar
• Dela Cadena RA, Stadnicki A, Uknis AB, et al. (1995). Inhibition of plasma kallikrein prevents peptidoglycan-induced arthritis in the Lewis rat. FASEB J: Off Publ Federation Am Soc Exp Biol 9:446–52
   PubMed Web of Science ®Google Scholar
• Dendorfer A, Wolfrum S, Dominiak P. (1999). Pharmacology and cardiovascular implications of the kinin-kallikrein system. Jap J Pharmacol 79:403–26
   PubMedGoogle Scholar
• Derkx FH, Bouma BN, Schalekamp MP, Schalekamp MA. (1979). An intrinsic factor XII- prekallikrein-dependent pathway activates the human plasma renin-angiotensin system. Nature 280:315–16
   PubMed Web of Science ®Google Scholar
• Dhar S, Bhargava R, Yunes M, et al. (2001). Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 7:3393–8
   PubMed Web of Science ®Google Scholar
• Diamandis EP, Yu H, Lopez-Otin C. (1996). Prostate specific antigen – a new constituent of breast cyst fluid. Breast Cancer Res Treatm 38:259–64
   PubMed Web of Science ®Google Scholar
• Dlamini Z, Bhoola KD. (2005). Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma. J Clin Pathol 58:915–22
   PubMed Web of Science ®Google Scholar
• Dominek P, Campagnolo P, H-Zadeh M, et al. (2010). Role of human tissue kallikrein in gastrointestinal stromal tumour invasion. Br J Cancer 103:1422–31
   PubMed Web of Science ®Google Scholar
• Drapeau G, deBlois D, Marceau F. (1991). Hypotensive effects of Lys-des-Arg9-bradykinin and metabolically protected agonists of B1 receptors for kinins. J Pharmacol Exp Therapeutics 259:997–1003
   PubMed Web of Science ®Google Scholar
• Duka A, Duka I, Gao G, et al. (2006). Role of bradykinin B1 and B2 receptors in normal blood pressure regulation. Am J Physiol Endocrinol Metabol 291:E268–74
   PubMed Web of Science ®Google Scholar
• Erdos EG. (1979). Enzyme inhibitors of the kallikrein and renin systems: introduction. Fed Proc 38:2751–2
   PubMedGoogle Scholar
• Erices R, Corthorn J, Lisboa F, Valdes G. (2011). Bradykinin promotes migration and invasion of human immortalized trophoblasts. Reprod Biol Endocrinol 9:97
   PubMed Web of Science ®Google Scholar
• Fernando AN, Fernando LP, Fukuda Y, Kaplan AP. (2005). Assembly, activation, and signaling by kinin-forming proteins on human vascular smooth muscle cells. AmJ Physiol Heart Circul Physiol 289:H251–7
   PubMed Web of Science ®Google Scholar
• Fernando LP, Natesan S, Joseph K, Kaplan AP. (2003). High molecular weight kininogen and factor XII binding to endothelial cells and astrocytes. Thrombosis Haemostasis 90:787–95
   PubMed Web of Science ®Google Scholar
• Ferreira SH, Vane JR. (1967). The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br J Pharmacol Chemotherapy 30:417–24
   PubMed Web of Science ®Google Scholar
• Figueroa CD, Henderson LM, Kaufmann J, et al. (1992). Immunovisualization of high (HK) and low (LK) molecular weight kininogens on isolated human neutrophils. Blood 79:754–9
   PubMed Web of Science ®Google Scholar
• Fink E, Bhoola KD, Snyman C, et al. (2007). Cellular expression of plasma prekallikrein in human tissues. Biol Chem 388:957–63
   PubMed Web of Science ®Google Scholar
• Fisher CA, Schmaier AH, Addonizio VP, Colman RW. (1982). Assay of prekallikrein in human plasma: comparison of amidolytic, esterolytic, coagulation, and immunochemical assays. Blood 59:963–70
   PubMed Web of Science ®Google Scholar
• Fong D, Smith DI, Hsieh WT. (1991). The human kininogen gene (KNG) mapped to chromosome 3q26-qter by analysis of somatic cell hybrids using the polymerase chain reaction. Human Genetics 87:189–92
   PubMed Web of Science ®Google Scholar
• Frey EK. (1962). The kallikrein inactivator and its clinical use. Med Klin 57:875–7
   PubMedGoogle Scholar
• Frick IM, Akesson P, Herwald H, et al. (2006). The contact system – a novel branch of innate immunity generating antibacterial peptides. EMBO J 25:5569–78
   PubMed Web of Science ®Google Scholar
• Gao L, Smith RS, Chen LM, et al. (2010). Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. Biol Chem 391:803–12
   PubMed Web of Science ®Google Scholar
• Giangrande PL. (2003). Six characters in search of an author: the history of the nomenclature of coagulation factors. Br J Haematol 121:703–12
   PubMed Web of Science ®Google Scholar
• Gordon EM, Gallagher CA, Johnson TR, et al. (1990). Hepatocytes express blood coagulation factor XII (Hageman factor). J Lab Clin Med 115:463–9
   PubMed Web of Science ®Google Scholar
• Goyal J, Smith KM, Cowan JM, et al. (1998). The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 58:4782–6
   PubMed Web of Science ®Google Scholar
• Graf K, Gräfe M, Auch-Schwelk W, et al. (1992). Bradykinin degrading activity in cultured human endothelial cells. J Cardiovasc Pharmacol 20:S16–20
   PubMed Web of Science ®Google Scholar
• Greco S, Muscella A, Elia MG, et al. (2004). Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. J Cellular Physiol 201:84–96
   PubMed Web of Science ®Google Scholar
• Gustafson EJ, Schutsky D, Knight LC, Schmaier AH. (1986). High molecular weight kininogen binds to unstimulated platelets. J Clin Invest 78:310–18
   PubMed Web of Science ®Google Scholar
• Gutkind JS. (1998). The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem 273:1839–42
   PubMed Web of Science ®Google Scholar
• Hall JM. (1992). Bradykinin receptors: pharmacological properties and biological roles. Pharmacol Therapeutics 56:131–90
   PubMed Web of Science ®Google Scholar
• Hasan AA, Amenta S, Schmaier AH. (1996). Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation 94:517–28
   PubMed Web of Science ®Google Scholar
• Hassan S, Sainz IM, Khan MM, et al. (2007). Antithrombotic activity of kininogen is mediated by inhibitory effects of domain 3 during arterial injury in vivo. Am J Physiol Heart Circul Physiol 292:H2959–65
   PubMed Web of Science ®Google Scholar
• Hillmeister P, Persson PB. (2012). The kallikrein–kinin system. Acta Physiol 206:215–19
   PubMed Web of Science ®Google Scholar
• Ignjatovic T, Tan F, Brovkovych V, et al. (2002). Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J Biol Chem 277:16847–52
   PubMed Web of Science ®Google Scholar
• Ishihara K, Kamata M, Hayashi I, et al. (2002). Roles of bradykinin in vascular permeability and angiogenesis in solid tumor. Int Immunopharmacol 2:499–509
   PubMed Web of Science ®Google Scholar
• Iwai N, Matsunaga M, Kita T, et al. (1988). Detection of low molecular kininogen messenger RNA in human kidney. J Hypertension Suppl: Off J Int Soc Hypertension 6:S399–400
   Web of Science ®Google Scholar
• Johnson AR, Skidgel RA, Gafford JT, Erdos EG. (1984). Enzymes in placental microvilli: angiotensin I converting enzyme, angiotensinase A, carboxypeptidase, and neutral endopeptidase (“enkephalinase”). Peptides 5:789–96
   PubMed Web of Science ®Google Scholar
• Joseph K, Tholanikunnel BG, Kaplan AP. (2002). Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci USA 99:896–900
   PubMed Web of Science ®Google Scholar
• Kakoki M, McGarrah RW, Kim HS, Smithies O. (2007). Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci USA 104:7576–81
   PubMed Web of Science ®Google Scholar
• Kanjanapongkul S. (2011). Report 2 cases of congenital factor XII deficiency: a rare coagulation disorder. J Med Assoc Thailand = Chotmaihet thangphaet 94:S231–2
   PubMedGoogle Scholar
• Kaplan AP, Joseph K, Shibayama Y, et al. (1997). The intrinsic coagulation/kinin-forming cascade: assembly in plasma and cell surfaces in inflammation. Adv Immunol 66:225–72
   PubMed Web of Science ®Google Scholar
• Keil C, Maskos K, Than M, et al. (2007). Crystal structure of the human carboxypeptidase N (kininase I) catalytic domain. J Mol Biol 366:504–16
   PubMed Web of Science ®Google Scholar
• Keith JC Jr, Sainz IM, Isordia-Salas I, et al. (2005). A monoclonal antibody against kininogen reduces inflammation in the HLA-B27 transgenic rat. Arthritis Res Therapy 7:R769–76
   PubMed Web of Science ®Google Scholar
• Khan MM, Bradford HN, Isordia-Salas I, et al. (2006). High-molecular-weight kininogen fragments stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in monocytes. Arteriosclerosis Thrombosis Vas Biol 26:2260–6
   PubMed Web of Science ®Google Scholar
• Kitamura N, Kitagawa H, Fukushima D, et al. (1985). Structural organization of the human kininogen gene and a model for its evolution. J Biol Chem 260:8610–17
   PubMed Web of Science ®Google Scholar
• Kolte D, Osman N, Yang J, Shariat-Madar Z. (2011). High molecular weight kininogen activates B2 receptor signaling pathway in human vascular endothelial cells. J Biol Chem 286:24561–71
   PubMed Web of Science ®Google Scholar
• Kontos CK, Chantzis D, Papadopoulos IN, Scorilas A. (2013). Kallikrein-related peptidase 4 (KLK4) mRNA predicts short-term relapse in colorectal adenocarcinoma patients. Cancer Lett 330:106–12
   PubMed Web of Science ®Google Scholar
• Kontos CK, Scorilas A. (2012). Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin Chem Lab Med 50:1877–91
   PubMed Web of Science ®Google Scholar
• Krijanovski Y, Proulle V, Mahdi F, et al. (2003). Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient: insights into structural requirements for kininogen expression. Blood 101:4430–6
   PubMed Web of Science ®Google Scholar
• Kuoppala A, Lindstedt KA, Saarinen J, et al. (2000). Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma. Am J Physiol Heart Circul Physiol 278:H1069–74
   PubMed Web of Science ®Google Scholar
• Leeb-Lundberg LMF. (2004). Bradykinin specificity and signaling at GPR100 and B-2 kinin receptors. Br J Pharmacol 143:931–2
   PubMed Web of Science ®Google Scholar
• Levin Y, Skidgel RA, Erdos EG. (1982). Isolation and characterization of the subunits of human plasma carboxypeptidase N (kininase i). Proc Natl Acad Sci USA 79:4618–22
   PubMed Web of Science ®Google Scholar
• Liebmann C. (2001). Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell Signal 13:777–85
   PubMed Web of Science ®Google Scholar
• Liesmaa I, Leskinen HK, Kokkonen JO, et al. (2009). Hypoxia-induced expression of bradykinin type-2 receptors in endothelial cells triggers NO production, cell migration, and angiogenesis. J Cell Physiol 221:359–66
   PubMed Web of Science ®Google Scholar
• Liu Y, Pixley R, Fusaro M, et al. (2009). Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway. Oncogene 28:2756–65
   PubMed Web of Science ®Google Scholar
• MacDonald RJ, Margolius HS, Erdos EG. (1988). Molecular biology of tissue kallikrein. Biochem J 253:313–21
   PubMed Web of Science ®Google Scholar
• Maeda H, Akaike T, Wu J, et al. (1996). Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology 33:222–30
   PubMed Web of Science ®Google Scholar
• Maeda H, Fang J, Inutsuka T, Kitamoto Y. (2003). Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 3:319–28
   PubMed Web of Science ®Google Scholar
• Mandle RJ, Colman RW, Kaplan AP. (1976). Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 73:4179–83
   PubMed Web of Science ®Google Scholar
• Mann EA, Lingrel JB. (1991). Developmental and tissue-specific expression of rat T-kininogen. Biochem Biophys Res Commun 174:417–23
   PubMed Web of Science ®Google Scholar
• Marceau F, Hess JF, Bachvarov DR. (1998). The B-1 receptors for kinins. Pharmacol Rev 50:357–86
   PubMed Web of Science ®Google Scholar
• Marcondes S, Antunes E. (2005). The plasma and tissue kininogen-kallikrein-kinin system: role in the cardiovascular system. Current Med Chem Cardiovas Hematol Agents 3:33–44
   PubMedGoogle Scholar
• Matthews KW, Wetsel RA. (2001). Characterization of mouse carboxypeptidase N small active subunit gene structure. J Immunol 166:6196–202
   PubMed Web of Science ®Google Scholar
• McLean PG, Perretti M, Ahluwalia A. (2000). Kinin B(1) receptors and the cardiovascular system: regulation of expression and function. Cardiovas Res 48:194–210
   PubMed Web of Science ®Google Scholar
• McMullen BA, Fujikawa K. (1985). Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor). J Biol Chem 260:5328–41
   PubMed Web of Science ®Google Scholar
• Meini S, Bellucci F, Cucchi P, et al. (2004). Bradykinin B2 and GPR100 receptors: a paradigm for receptor signal transduction pharmacology. Br J Pharmacol 143:938–41
   PubMed Web of Science ®Google Scholar
• Montana V, Sontheimer H. (2011). Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci: Off J Soc Neurosci 31:4858–67
   PubMed Web of Science ®Google Scholar
• Morbidelli L, Parenti A, Giovannelli L, et al. (1998). B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF-2 effects. Br J Pharmacol 124:1286–92
   PubMed Web of Science ®Google Scholar
• Moreau ME, Garbacki N, Molinaro G, et al. (2005). The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 99:6–38
   PubMed Web of Science ®Google Scholar
• Morrison DC, Cochrane CG. (1974). Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med 140:797–811
   PubMed Web of Science ®Google Scholar
• Motta G, Shariat-Madar Z, Mahdi F, et al. (2001). Assembly of high molecular weight kininogen and activation of prekallikrein on cell matrix. Thrombosis Haemostasis 86:840–7
   PubMed Web of Science ®Google Scholar
• Nakao T, Yamane T, Katagami T, et al. (2011). Severe prekallikrein deficiency due to a homozygous Trp499Stop nonsense mutation. Blood Coagul Fibrinol: Int J Haemostasis Thrombosis 22:337–9
   PubMed Web of Science ®Google Scholar
• Nowak W, Errasti AE, Armesto AR, et al. (2011). Endothelial angiotensin-converting enzyme and neutral endopeptidase in isolated human umbilical vein: an effective bradykinin inactivation pathway. EurJ Pharmacol 667:271–7
   PubMed Web of Science ®Google Scholar
• Okamoto H, Takano M, Yokoyama K, et al. (1996). Fibroblasts synthesize kininogen in response to inflammatory mediators. Immunopharmacology 32:28–33
   PubMedGoogle Scholar
• Oliver JA, Monroe DM, Roberts HR, Hoffman M. (1999). Thrombin Activates Factor XI on Activated Platelets in the Absence of Factor XII. Arteriosclerosis, Thrombosis Vas Biol 19:170–7
   PubMed Web of Science ®Google Scholar
• Palmieri FE, Bausback HH, Churchill L, Ward PE. (1986). Kinin and enkephalin conversion by an endothelial, plasma membrane carboxypeptidase. Biochem Pharmacol 35:2749–56
   PubMed Web of Science ®Google Scholar
• Parish LC. (2011). Hereditary angioedema: diagnosis and management – a perspective for the dermatologist. J Am Acad Dermatol 65:843–50
   PubMed Web of Science ®Google Scholar
• Partin AW, Carter HB, Chan DW, et al. (1990). Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143:747–52
   PubMed Web of Science ®Google Scholar
• Prenzel N, Zwick E, Daub H, et al. (1999). EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402:884–8
   PubMed Web of Science ®Google Scholar
• Puri RN, Zhou F, Hu CJ, et al. (1991). High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets. Blood 77:500–7
   PubMed Web of Science ®Google Scholar
• Ratnoff OD, Margolius AJ. (1955). Hageman trait: an asymptomatic disorder of blood coagulation. Trans Assoc Am Phys 68:149–54
   PubMedGoogle Scholar
• Regoli D, Barabe J. (1980). Pharmacology of bradykinin and related kinins. Pharmacol Rev 32:1–46
   PubMed Web of Science ®Google Scholar
• Renne T. (2012). The procoagulant and proinflammatory plasma contact system. Sem Immunopathol 34:31–41
   PubMed Web of Science ®Google Scholar
• Renné T, Schmaier AH, Nickel KF, et al. (2012). In vivo roles of factor XII. Blood 120:4296–303
   PubMed Web of Science ®Google Scholar
• Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. (1998). Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 35:275–368
   PubMed Web of Science ®Google Scholar
• Rocha e Silva M, Beraldo WT, Rosenfeld G. (1949). Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Physiol 156:261–73
   PubMed Web of Science ®Google Scholar
• Rojkjaer R, Hasan AA, Motta G, et al. (1998). Factor XII does not initiate prekallikrein activation on endothelial cells. Thrombosis Haemostasis 80:74–81
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. (2004). The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia: Off J Leukemia Soc Am, Leukemia Res Fund, UK 18:362–5
   PubMed Web of Science ®Google Scholar
• Sainz IM, Pixley RA, Colman RW. (2007). Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thrombosis Haemostasis 98:77–83
   PubMed Web of Science ®Google Scholar
• Saito H, Ratnoff OD, Pensky J. (1976). Radioimmunoassay of human Hageman factor (factor XII). J Lab Clin Med 88:506–14
   PubMed Web of Science ®Google Scholar
• Salvesen G, Parkes C, Abrahamson M, et al. (1986). Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem J 234:429–34
   PubMed Web of Science ®Google Scholar
• Sartor RB, DeLa Cadena RA, Green KD, et al. (1996). Selective kallikrein-kinin system activation in inbred rats differentially susceptible to granulomatous enterocolitis. Gastroenterology 110:1467–81
   PubMed Web of Science ®Google Scholar
• Schapira M, Despland E, Scott CF, et al. (1982). Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 69:1199–202
   PubMed Web of Science ®Google Scholar
• Schmaier AH. (2002). The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J Clin Invest 109:1007–9
   PubMed Web of Science ®Google Scholar
• Schmaier AH. (2003). The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Phys – Regul, Integr Compar Physiol 285:R1–13
   PubMed Web of Science ®Google Scholar
• Schmaier AH. (2008). The elusive physiologic role of Factor XII. J Clin Invest 118:3006–9
   PubMed Web of Science ®Google Scholar
• Schmaier AH, Bradford H, Silver LD, et al. (1986). High molecular weight kininogen is an inhibitor of platelet calpain. J Clin Invest 77:1565–73
   PubMed Web of Science ®Google Scholar
• Schmaier AH, Kuo A, Lundberg D, et al. (1988). The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 263:16327–33
   PubMed Web of Science ®Google Scholar
• Scott CF, Colman RW. (1980). Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. J Clin Invest 65:413–21
   PubMed Web of Science ®Google Scholar
• Seegers HC, Avery PS, McWilliams DF, et al. (2004). Combined effect of bradykinin B2 and neurokinin-1 receptor activation on endothelial cell proliferation in acute synovitis. FASEB J: Off Publ Fed Am Soc Exp Biol 18:762–4
   PubMed Web of Science ®Google Scholar
• Shariat-Madar Z, Mahdi F, Schmaier AH. (2002). Assembly and activation of the plasma kallikrein/kinin system: a new interpretation. Int Immunopharmacol 2:1841–9
   PubMed Web of Science ®Google Scholar
• Shariat-Madar Z, Schmaier AH. (2004). Review: the plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis. J Endotoxin Res 10:3–13
   PubMedGoogle Scholar
• Sheikh IA, Kaplan AP. (1986a). Studies of the digestion of bradykinin, Lys-bradykinin, and des-Arg9-bradykinin by angiotensin converting enzyme. Biochem Pharmacol 35:1951–6
   PubMed Web of Science ®Google Scholar
• Sheikh IA, Kaplan AP. (1986b). Studies of the digestion of bradykinin, lysyl bradykinin, and kinin-degradation products by carboxypeptidases A, B, and N. Biochem Pharmacol 35:1957–63
   PubMed Web of Science ®Google Scholar
• Sheng N, Fairbanks MB, Heinrikson RL, et al. (2000). Cleaved high molecular weight kininogen binds directly to the integrin CD11b/CD18 (Mac-1) and blocks adhesion to fibrinogen and ICAM-1. Blood 95:3788–95
   PubMed Web of Science ®Google Scholar
• Skidgel RA, Erdos EG. (1998). Cellular carboxypeptidases. Immunol Rev 161:129–41
   PubMed Web of Science ®Google Scholar
• Skidgel RA, Johnson AR, Erdos EG. (1984). Hydrolysis of opioid hexapeptides by carboxypeptidase N. Presence of carboxypeptidase in cell membranes. Biochem Pharmacol 33:3471–8
   PubMed Web of Science ®Google Scholar
• Skidgel RA, Kawahara MS, Hugli TE. (1986). Functional significance of the subunits of carboxypeptidase N (kininase I). Adv Exp Med Biol 198, Pt A:375–80
   PubMedGoogle Scholar
• Skidgel RA, Davis RM, Tan F. (1989). Human carboxypeptidase M. Purification and characterization of a membrane-bound carboxypeptidase that cleaves peptide hormones. J Biol Chem 264:2236–41
   PubMed Web of Science ®Google Scholar
• Stavrou E, Schmaier AH. (2010). Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thrombosis Res 125:210–15
   PubMed Web of Science ®Google Scholar
• Stege R, Grande M, Carlstrom K, et al. (2000). Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clinical Cancer Res: Off J Am Assoc Cancer Res 6:160–5
   PubMed Web of Science ®Google Scholar
• Stone OA, Richer C, Emanueli C, et al. (2009). Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arteriosc Thrombosis Vas Biol 29:657–64
   PubMed Web of Science ®Google Scholar
• Takada Y, Skidgel RA, Erdos EG. (1985). Purification of human urinary prokallikrein. Identification of the site of activation by the metalloproteinase thermolysin. Biochem J 232:851–8
   PubMed Web of Science ®Google Scholar
• Takano M, Yokoyama K, Yayama K, Okamoto H. (1995). Rat fibroblasts synthesize T-kininogen in response to cyclic-AMP, prostaglandin E2 and cytokines. Biochim Biophys Acta 1268:107–14
   PubMed Web of Science ®Google Scholar
• Talieri M, Li L, Zheng Y, Alexopoulou DK, et al. (2009). The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. British J Cancer 100:1659–65
   PubMed Web of Science ®Google Scholar
• Taub JS, Guo R, Leeb-Lundberg LM, et al. (2003). Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res 63:2037–41
   PubMed Web of Science ®Google Scholar
• Thompson RE, Mandle R, Kaplan AP. (1977). Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 60:1376–80
   PubMed Web of Science ®Google Scholar
• Vergiliana JF, Asokananthan N, Stewart GA. (2010). Activation of the plasma kallikrein--kinin system on human lung epithelial cells. Biol Chem 391:1067–77
   PubMed Web of Science ®Google Scholar
• Wachtfogel YT, Kucich U, James HL, et al. (1983). Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 72:1672–7
   PubMed Web of Science ®Google Scholar
• Wang JW, Su W, Law YP, et al. (2001). Mechanism of bradykinin-induced Ca(2+) mobilization in MG63 human osteosarcoma cells. Hormone Res 55:265–70
   PubMedGoogle Scholar
• Whitehouse RC, Prasad AS, Rabbani PI, Cossack ZT. (1982). Zinc in plasma, neutrophils, lymphocytes, and erythrocytes as determined by flameless atomic absorption spectrophotometry. Clin Chem 28:475–80
   PubMed Web of Science ®Google Scholar
• Wolf WC, Evans DM, Chao L, Chao J. (2001). A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol 159:1797–805
   PubMed Web of Science ®Google Scholar
• Wu J, Akaike T, Hayashida K, et al. (2002). Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 98:29–35
   PubMed Web of Science ®Google Scholar
• Wunderer G, Walter I, Muller E, Henschen A. (1986). Human Ile-Ser-bradykinin, identical with rat T-kinin, is a major permeability factor in ovarian carcinoma ascites. Biol Chem Hoppe-Seyler 367:1231–4
   PubMed Web of Science ®Google Scholar
• Yamada K, Erdos EG. (1982). Kallikrein and prekallikrein of the isolated basolateral membrane of rat kidney. Kidney Int 22:331–7
   PubMed Web of Science ®Google Scholar
• Yang CM, Chien CS, Ma YH, et al. (2003). Bradykinin B2 receptor-mediated proliferation via activation of the Ras/Raf/MEK/MAPK pathway in rat vascular smooth muscle cells. J Biomed Sci 10:208–18
   PubMed Web of Science ®Google Scholar
• Yang WH, Chang JT, Hsu SF, et al. (2010). Bradykinin enhances cell migration in human chondrosarcoma cells through BK receptor signaling pathways. J Cell Biochem 109:82–92
   PubMed Web of Science ®Google Scholar
• Yousef GM, Diamandis EP. (2001). The new human tissue kallikrein gene family: structure, function, and association to disease. Endocrine Rev 22:184–204
   PubMed Web of Science ®Google Scholar
• Yousef GM, Diamandis EP. (2002). Expanded human tissue kallikrein family – a novel panel of cancer biomarkers. Tumor Biol 23:185–92
   PubMedGoogle Scholar
• Yu H, Anderson PJ, Freedman BI, et al. (2000). Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease. Genomics 69:225–34
   PubMed Web of Science ®Google Scholar
• Zhang JC, Claffey K, Sakthivel R, et al. (2000). Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J: Off Publ Fed Am Soc Exp Biol 14:2589–600
   PubMed Web of Science ®Google Scholar
• Zhang WP, Bhola N, Kalyankrishna S, et al. (2008). Kinin B2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Mol Cancer Res 6:1946–56
   PubMed Web of Science ®Google Scholar
• Zhang X, Tan F, Brovkovych V, et al. (2011). Cross-talk between carboxypeptidase M and the kinin B1 receptor mediates a new mode of G protein-coupled receptor signaling. J Biol Chem 286:18547–61
   PubMedGoogle Scholar
• Zhao YS, Xue YX, Liu YH, et al. (2005). Study of correlation between expression of bradykinin B-2 receptor and pathological grade in human gliomas. Br J Neurosurg 19:322–6
   PubMed Web of Science ®Google Scholar